Benjamin Mou

Behandeling With Stereotactic Ablative Radiotherapie for Patiënten met up to 5 Oligogemetastaseerd Cancer Lesions: Langetermijn Uitkomsten of the Nongerandomiseerde Population-based Fase 2-SABR-5 Klinische trial

Evaluating Toxicity and Interaction Uitkomsten of Systemic Therapy and Stereotactic Ablative Radiotherapie for Oligogemetastaseerd Disease: A Secondary Analyse of the Fase 2-SABR-5 Trial

The Impact van Ultracentral Tumor Location on Uitkomsten in Patients with Pulmonary Oligometastases: A Secondary Analyse of the Single-Arm Fase 2-SABR-5 Trial